share_log

Processa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Processa Pharmaceuticals | 10-Q: Q3 2024 Earnings Report

Processa Pharmaceuticals | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/31 04:07

Moomoo AI 已提取核心信息

Processa Pharmaceuticals reported a net loss of $9.1 million for the nine months ended September 30, 2024, compared to $8.7 million in the same period of 2023. Research and development expenses increased to $5.6 million from $4.5 million, primarily due to costs associated with the NGC-Cap clinical trials. The company ended the quarter with $2.9 million in cash and cash equivalents.The company achieved significant milestones in its NGC-Cap program, receiving IND clearance in July 2024 and dosing the first patient in its Phase 2 breast cancer trial on October 2, 2024. During the period, Processa strengthened its financial position by raising $6.3 million through a public offering in January and an additional $931,000 through an ATM offering in July 2024.Management acknowledges the need for additional funding to continue operations beyond the next twelve months. The company is exploring various financing options, including equity offerings, debt financing, and strategic partnerships to support its clinical development programs, particularly the ongoing Phase 2 trial of NGC-Cap and advancement of other pipeline candidates NGC-Gem and NGC-Iri.
Processa Pharmaceuticals reported a net loss of $9.1 million for the nine months ended September 30, 2024, compared to $8.7 million in the same period of 2023. Research and development expenses increased to $5.6 million from $4.5 million, primarily due to costs associated with the NGC-Cap clinical trials. The company ended the quarter with $2.9 million in cash and cash equivalents.The company achieved significant milestones in its NGC-Cap program, receiving IND clearance in July 2024 and dosing the first patient in its Phase 2 breast cancer trial on October 2, 2024. During the period, Processa strengthened its financial position by raising $6.3 million through a public offering in January and an additional $931,000 through an ATM offering in July 2024.Management acknowledges the need for additional funding to continue operations beyond the next twelve months. The company is exploring various financing options, including equity offerings, debt financing, and strategic partnerships to support its clinical development programs, particularly the ongoing Phase 2 trial of NGC-Cap and advancement of other pipeline candidates NGC-Gem and NGC-Iri.
Processa Pharmaceuticals报告了截至2024年9月30日的九个月净亏损910万美元，而2023年同期的亏损为870万美元。研究和开发费用由450万美元增加到560万美元，主要是由于与NGC-Cap临床试验相关的成本。公司季度末的现金及现金等价物为290万美元。公司在其NGC-Cap项目上取得了重大里程碑，于2024年7月获得IND批准，并于2024年10月2日对第一位乳腺癌试验患者进行给药。在此期间，Processa通过2024年1月的公开发行筹集了630万美元，并通过2024年7月的ATm发行额外筹集了93.1万美元，从而增强了其财务状况。管理层承认需要额外资金以继续运营，超出接下来的十二个月。该公司正在探索各种融资选项，包括股权发行、债务融资以及战略合作伙伴关系，以支持其临床开发项目，特别是正在进行的NGC-Cap二期试验以及其他管线候选药物NGC-Gem和NGC-Iri的推进。
Processa Pharmaceuticals报告了截至2024年9月30日的九个月净亏损910万美元，而2023年同期的亏损为870万美元。研究和开发费用由450万美元增加到560万美元，主要是由于与NGC-Cap临床试验相关的成本。公司季度末的现金及现金等价物为290万美元。公司在其NGC-Cap项目上取得了重大里程碑，于2024年7月获得IND批准，并于2024年10月2日对第一位乳腺癌试验患者进行给药。在此期间，Processa通过2024年1月的公开发行筹集了630万美元，并通过2024年7月的ATm发行额外筹集了93.1万美元，从而增强了其财务状况。管理层承认需要额外资金以继续运营，超出接下来的十二个月。该公司正在探索各种融资选项，包括股权发行、债务融资以及战略合作伙伴关系，以支持其临床开发项目，特别是正在进行的NGC-Cap二期试验以及其他管线候选药物NGC-Gem和NGC-Iri的推进。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    热门讨论
    特朗普2.0时代开启，全球市场会如何演变？
    🎙️讨论： 1. 关税政策将如何影响美股、黄金、比特币等核心资产的走势？ 2. 在此背景下，有哪些投资机会值得关注？你会如何布局？ 展开
    MicroStrategy 2024年第四季度业绩电话会
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。